"The move toward DTC access should not be viewed as a short-term marketing trend, but rather a strategic reconfiguration of the pharmaceutical value chain ... DTC models let manufacturers control pricing, data ownership and delivery. This changes the traditional role of [PBMs] as intermediaries. The launch of TrumpRx further underscores growing policy support for bypassing PBMs entirely."  MORE >>